Financial Data and Research Support for Biocon
Biocon’s financial performance has been impressive, with consistent growth driven by its biosimilars , biologics , and insulin products . The company’s strong pipeline, increasing presence in emerging markets, and strategic collaborations have contributed significantly to its revenue generation. 1. Recent Financial Performance Biocon’s annual financial report for FY 2023 highlights a consistent growth trajectory across its key business segments: Revenue Growth : Biocon’s consolidated revenue for FY 2023 stood at ₹12,208 crores (approx. $1.5 billion) , reflecting a 9% growth compared to the previous year. Biosimilars and Biologics : The biologics and biosimilars segments contributed significantly to the company’s revenue, with biosimilars accounting for 41% of total sales. Biocon’s biosimilar partnerships , particularly with Mylan , have been a major factor in this growth. Profitability : Biocon’s net profit for FY 2023 was ₹1,295 crores (approx. $160 million) , reflecting a ...